| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| ISIN code | US5324571083 |
| Industry group | Pharmaceuticals |
| Aligned with SDGs |
Founded in 1876, Eli Lilly is a global pharmaceutical company, with a strong legacy of pharmaceutical innovation, including the mass production of insulin, vaccines (e.g. polio), antidepressants and other breakthrough therapies, helping shape the modern pharmaceutical industry. It operates in a single business segment, Human Pharmaceuticals, which covers major therapeutic areas including endocrinology (notably diabetes and obesity), neuroscience, immunology, oncology, and cardiovascular therapies. The company serves healthcare providers, hospitals, governments, and wholesalers in more than 120 countries, with major markets in North America, Europe, and Asia-Pacific.
Investment rationale
Eli Lilly’s medicine portfolio targets conditions responsible for the majority of global mortality and morbidity. Its most transformative therapies, targeting diabetes and obesity, heart failure and kidney disease, reduce long-term morbidity and healthcare-system burden, while innovations in oncology and neuro-degeneration expand treatment options in historically underserved areas. Lilly reinforces this impact through sustained investment in high-risk scientific research, large-scale manufacturing expansions, global access and affordability programs, and partnerships aimed at addressing antimicrobial resistance and other major health threats. Together, these elements position Lilly as a company whose medicines and innovation strategy contribute substantially to public health, medical progress, and broader societal wellbeing.
The contribution to the Wellbeing Transition comes from 100% of revenues related to the impact objective Health Care.